Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epratuzumab open-label extension in systemic lupus erythematosus
ACTRN12612000298819Phase 3Recruiting
- Sponsor
- UCB
- Start
- Jul 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 28
01
Overview
Phase 3, open-label trial of epratuzumab in systemic lupus erythematosus (SLE), sponsored by UCB. Primary endpoint: Treatment response at Week 48 and Week 96. Started Jul 2011; status: recruiting.
02
Drugs
epratuzumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ACTRN12612000298819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000298819.